Readystate Asset Management LP acquired a new position in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 295,038 shares of the company’s stock, valued at approximately $684,000. Readystate Asset Management LP owned 0.24% […]
Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 […]
Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) was upgraded by equities researchers at Truist Financial from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, Benzinga reports. The firm presently has a $9.00 price objective on the stock. Truist Financial’s price target would indicate a potential upside of 85.57% […]
Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) will be issuing its quarterly earnings data before the market opens on Wednesday, February 28th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Mersana Therapeutics Stock Performance Mersana Therapeutics stock traded up $0.17 during mid-day trading on Thursday, reaching $3.86. The company’s […]
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) saw a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 6,650,000 shares, a decline of 10.0% from the January 15th total of 7,390,000 shares. Based on an average daily trading volume, of 1,900,000 shares, the short-interest […]